Christopher Michael Pieczonka

机构：SUNY Upstate Medical University · ORCID：0000-0002-2531-7587

发表论文 184 篇 · 总被引 1953 次 · h-index 18

代表论文

• Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (2025 · New England Journal of Medicine · 被引 42)
• Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study (2025 · Journal of Clinical Oncology · 被引 7)
• Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 5)
• DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis (2025 · Prostate Cancer and Prostatic Diseases · 被引 3)
• Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial (2025 · The Journal of Urology · 被引 2)
• LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer (2025 · Annals of Oncology · 被引 2)